评估新型耐药结核病治疗方案对早期传播的抑制作用
本研究利用人-豚鼠传播模型,评估含贝达喹啉和利奈唑胺的优化方案及BPaL方案对耐药结核病传播的影响。实验1中治疗72小时后豚鼠感染率无显著变化(27.8% vs 26.7%,P>.99);实验2中BPaL治疗72小时后感染率从44.4%降至0%(P<.0001)。
要点
- 含贝达喹啉和标准剂量利奈唑胺的方案治疗72小时未降低耐药结核病传播。
- BPaL方案治疗72小时快速完全抑制耐药结核病传播。
- BPaL对传播的早期影响显著,但需进一步研究。
核心结论
- 含贝达喹啉和标准剂量利奈唑胺的耐药结核病方案治疗72小时未降低传播。
- BPaL方案治疗72小时快速完全抑制传播,提示对传播有早期且 profound 的影响。
研究设计与样本
- 采用人-豚鼠传播模型。
- 实验1:患者启动含贝达喹啉和利奈唑胺的优化耐药结核病方案。
- 实验2:患者启动BPaL方案(贝达喹啉、1200 mg利奈唑胺和pretomanid)。
- 每个队列基线传染性通过将病房空气排入两个豚鼠暴露室之一(对照组,每个房间90只豚鼠)持续8患者日测量,治疗72小时后将病房空气排入第二个豚鼠暴露室持续8患者日(干预组)。
- 通过基线(治疗前)和暴露期后6周对豚鼠进行结核菌素皮肤试验比较传染性。
主要发现
- 实验1:治疗前,5例耐药结核病患者感染90只豚鼠中的24只(26.7%)(对照组);治疗72小时后,同一批患者感染90只豚鼠中的25只(27.8%)(干预组)(P > .99)。
- 实验2:治疗前,9例耐药结核病患者感染90只豚鼠中的40只(44.4%)(对照组);治疗72小时后(开始于用药后72小时),同一批患者感染90只豚鼠中的0只(0%)(干预组)(P < .0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most drug-resistant tuberculosis occurs due to transmission of unsuspected or ineffectively treated drug-resistant tuberculosis. The duration of treatment to stop person-to-person spread of drug-resistant tuberculosis is uncertain. We evaluated the impact of novel regimens, including BPaL (bedaquiline, 1200-mg linezolid, and pretomanid), on drug-resistant tuberculosis transmission, using the human-guinea pig (H-GP) transmission model. METHODS: In experiment 1, patients initiated an optimized drug-resistant tuberculosis regimen including bedaquiline and linezolid. In experiment 2, patients initiated the BPaL regimen. We measured baseline infectivity for each cohort by exhausting ward air to one of two guinea pig exposure rooms (control group), each containing 90 guinea pigs, for 8 patient-days. Then, after 72 hours of treatment, ward air was exhausted to the second guinea pig exposure room for 8 patient-days (intervention group). The infectiousness of each cohort was compared by performing tuberculin skin tests in guinea pigs at baseline (before treatment) and 6 weeks after the exposure period. RESULTS: In experiment 1, before treatment, 5 patients with drug-resistant tuberculosis infected 24 of 90 guinea pigs (26.7%) (control group). After treatment (72 hours after drug initiation), the same patients infected 25 of 90 guinea pigs (27.8%) (intervention group) (P > .99). In experiment 2, before treatment, 9 patients with drug-resistant tuberculosis infected 40 of 90 guinea pigs (44.4%) (control group). After treatment (beginning 72 hours after drug initiation), the same patients infected 0 of 90 guinea pigs (0%) (intervention group) (P < .0001). CONCLUSIONS: In this study, drug-resistant tuberculosis drug regimens, including bedaquiline and standard-dose linezolid for 72 hours, did not decrease drug-resistant tuberculosis transmission. In contrast, transmission was rapidly and completely inhibited in patients treated with BPaL for 72 hours, suggesting an early and profound impact on transmission.
引用
- Stoltz A, Nathavitharana RR, de Kock E, et al. Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis. J Infect Dis. 2025. PMID: 39789858. doi:10.1093/infdis/jiaf005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。